Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYX-201 and Pembrolizumab in Advanced Solid Tumors
NCT06795412Phase 2Recruiting
- Sponsor
- Pyxis Oncology
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of micvotabart pelidotin in solid tumor (advanced stage), sponsored by Pyxis Oncology. Started Apr 2025; status: recruiting.
02
Drugs
micvotabart pelidotin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06795412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795412.